PolyModels Hub is a technology company.
PolyModels Hub has raised $10.0M across 2 funding rounds.
PolyModels Hub has raised $10.0M in total across 2 funding rounds.
PolyModels Hub has raised $10.0M in total across 2 funding rounds.
PolyModels Hub's investors include Marathon Venture Capital.
# High-Level Overview
PolyModels Hub is a biopharmaceutical software company that develops the digital backbone for drug development and manufacturing processes[1][3]. Founded in 2023, the company builds ModelFlow, an enterprise SaaS platform that replaces manual, fragmented laboratory experimentation with advanced modelling, simulation, and workflow automation[1][2].
The company serves a critical gap in the pharmaceutical industry: after scientists identify a target molecule for a new therapy, the process of turning it into a manufacturable product at scale remains heavily dependent on outdated, manual wet-lab experiments that can take weeks or months[4]. PolyModels Hub's platform enables pharmaceutical companies to design, test, and optimize drug development processes using data-driven automation instead. The company has already achieved significant traction, securing four of the world's top ten pharmaceutical companies as customers[1][4].
# Origin Story
PolyModels Hub was founded in 2023 by a team of scientists and engineers with deep pharmaceutical expertise[3]. The founding team is led by Antonio Benedetti and Charalampos Christodoulou, both former scientists at GlaxoSmithKline (GSK), alongside Antonio Yankey, a chemical engineer turned software engineer[4]. The broader team includes multiple PhDs and former leaders from major pharmaceutical companies including Eli Lilly, AstraZeneca, and Johnson & Johnson[1].
The company emerged from recognizing a fundamental inefficiency in biopharma: the process development phase—converting a promising molecule into a scalable, manufacturable product—relies on manual experimentation and fragmented workflows that create bottlenecks, delays, and enormous costs[4]. The founding team's direct experience in this space positioned them to build a solution that pharmaceutical scientists would actually trust and adopt.
# Core Differentiators
# Role in the Broader Tech Landscape
PolyModels Hub is riding a critical wave of digital transformation in biopharma, an industry that has historically lagged in automation and data-driven optimization compared to other sectors[4]. The timing is particularly favorable because:
Regulatory and economic pressure: Drug development costs continue to escalate, and regulatory bodies increasingly expect data-driven justification for manufacturing decisions. Digital process optimization directly addresses both concerns[4].
AI and simulation maturity: Advances in computational modelling and machine learning have made in-silico simulation viable at scale, enabling the replacement of physical experiments with digital twins[2].
Talent and infrastructure readiness: The pharmaceutical industry now has sufficient computational infrastructure and data literacy to adopt software-native workflows, whereas this was not true a decade ago[1].
The company influences the broader ecosystem by establishing a new standard for how drug development should operate—moving the industry away from manual, paper-based processes toward integrated, data-driven platforms. This shift has ripple effects across contract research organizations, manufacturing partners, and regulatory agencies.
# Quick Take & Future Outlook
PolyModels Hub is positioned to become essential infrastructure for modern drug development. The company's €7.8–7.9 million Series A funding (led by Molten Ventures with Marathon Venture Capital participation) signals strong investor confidence and provides runway for geographical expansion and product development across additional functions in the drug development lifecycle[1].
The company's trajectory will likely be shaped by:
PolyModels Hub exemplifies a broader trend: the digitization of traditionally analog, expertise-driven industries. By combining deep domain knowledge with modern software architecture, the company is not just building a tool—it's reshaping how an entire industry approaches one of its most critical and costly processes.
PolyModels Hub has raised $10.0M across 2 funding rounds. Most recently, it raised $9.0M Series A in November 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2025 | $9.0M Series A | Marathon Venture Capital | |
| Jul 1, 2024 | $1.0M Seed | Marathon Venture Capital |